ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York

ImageneBio will present at an H.C. Wainwright conference while advancing its anti-OX40 antibody, olevaprubart, in Phase 2b atopic dermatitis trials.

Rhea-AI Summary

ImageneBio (IMA)/b) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, with CEO Kristin Yarema, Ph.D., representing the company.The fireside chat is scheduled for 3:30 p.m. ET and will be webcast and archived for 90 days on ImageneBio's investor relations events page. ImageneBio is a clinical-stage biotechnology company developing therapeutics for immunological, autoimmune and inflammatory diseases, led by its non-depleting anti-OX40 monoclonal antibody program, olevaprubart. Phase 1b/2a trials of olevaprubart in atopic dermatitis and alopecia areata have been completed, and a Phase 2b trial in moderate-to-severe atopic dermatitis is ongoing.

Key Terms

monoclonal antibody, phase 2b clinical trial

2 terms

monoclonal antibody medical

"olevaprubart, is a receptor targeting, non-depleting anti-OX40 monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

phase 2b clinical trial medical

"currently conducting a Phase 2b clinical trial of olevaprubart"

A phase 2b clinical trial is a mid-stage medical study that tests whether a new treatment works and which dose is best by enrolling a larger group of patients than earlier phase 2 studies. For investors, its results are a key signal of a drug’s real-world effectiveness and safety, and can strongly influence the chances of later regulatory approval, future funding needs, and a company’s stock outlook—like a larger pilot test before full rollout.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14, 2026, and management will participate in one-on-one meetings.

H.C. Wainwright 28th Annual Global Investment Conference in New York
Fireside Chat: Monday, Sept. 14, 2026, 3:30pm ET
Webcast linked here and archived for 90 days on events page on the Imagene IR website

About ImageneBio, Inc.
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, olevaprubart, is a receptor targeting, non-depleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis.

Company and Investor Contact
Rebecca Cohen
rcohen@imagenebio.com

Media Contact
Jason Braco, PhD
Valence
jason@valencecomms.com

FAQ

When and how can investors access ImageneBio's H.C. Wainwright fireside chat?

The fireside chat is scheduled for Monday, September 14, 2026, at 3:30 p.m. ET. A webcast will be available via a link provided by the company and will be archived for 90 days on the events page of the ImageneBio investor relations website.

What is ImageneBio's lead program, olevaprubart, and its mechanism?

Olevaprubart is described as a receptor targeting, non-depleting anti-OX40 monoclonal antibody. The company highlights that it has multiple differentiating features compared with other approaches.

What clinical trial progress has ImageneBio reported for olevaprubart?

ImageneBio has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata. The company is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis.